anti-p53 t-cell receptor-transduced peripheral blood lymphocytes
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00393029)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Cellular tumor antigen p53Immunity, passive
TP53 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-p53 t-cell receptor-transduced peripheral blood lymphocytes
- anti-protein 53 or tumor protein 53 (p53) t-cell receptor transduced peripheral blood lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00704938 | Phase 2 | Jun 1, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00393029 | Phase 2 | Oct 1, 2006 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 2006 |
| National Institutes of Health (NIH) | Government | 2 | 1 | 1 | 2006 |
2 organizations
Page 1 / 1